BioXcel Therapeutics, Inc.
BTAI
$1.18
-$0.02-1.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.28% | 3.92% | 52.75% | 73.82% | 66.71% |
| Total Depreciation and Amortization | -2.91% | -2.26% | -2.24% | -2.85% | -2.83% |
| Total Amortization of Deferred Charges | 253.75% | 154.53% | 30.13% | -28.53% | -65.99% |
| Total Other Non-Cash Items | 144.72% | 230.14% | -656.63% | -229.22% | -177.15% |
| Change in Net Operating Assets | 394.88% | 126.49% | 1,244.67% | -135.97% | -80.37% |
| Cash from Operations | 20.01% | 30.76% | 47.06% | 44.86% | 53.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46.50% | 69.36% | -37.52% | -8.23% | 44.11% |
| Repurchase of Common Stock | 68.52% | -687.50% | -487.50% | -- | -100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -239.03% | -205.48% | -87.43% | -214.36% | 52.17% |
| Cash from Financing | 54.17% | 59.81% | -46.94% | -19.87% | 38.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.90% | 93.81% | 47.11% | 52.80% | 72.48% |